---
title: 'Long-term outcomes and renal responses following autologous hematopoietic
  stem cell transplantation for light chain deposition disease: a retrospective study
  on behalf of the Chronic Malignancies Working Party of the European Society for
  Blood and Marrow Transplantation'
date: '2024-03-28'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38546696/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240328180704&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: There is little long-term outcome data on the efficacy of autologous
  hematopoietic stem cell transplantation (ASCT) in light chain deposition disease
  (LCDD). We identified 51 LCDD patients in the EBMT registry who had undergone upfront
  ASCT between 1995 and 2021. The median serum creatinine was 280 μmol/L and 45% required
  renal replacement therapy (RRT) at time of transplant. The melphalan dose was 100mg/m2
  in 23%, 140mg/m2 in 55% and 200 mg/m2 in 21%. The rate of very good partial response
  ...
disable_comments: true
---
There is little long-term outcome data on the efficacy of autologous hematopoietic stem cell transplantation (ASCT) in light chain deposition disease (LCDD). We identified 51 LCDD patients in the EBMT registry who had undergone upfront ASCT between 1995 and 2021. The median serum creatinine was 280 μmol/L and 45% required renal replacement therapy (RRT) at time of transplant. The melphalan dose was 100mg/m2 in 23%, 140mg/m2 in 55% and 200 mg/m2 in 21%. The rate of very good partial response ...